Short communication: Algicide activity of antimicrobial peptides compounds against Prototheca bovis.
Sperotto. V R VR; Denardi. L B LB; Weiblen. C C; de Jesus. F P K FPK; Dorneles. M R MR; Ianiski. L B LB; Santurio. J M JM
Key Findings
- Pexiganan, h‑Lf1‑11, LL‑37, and cecropin B all inhibited the growth of Prototheca bovis in lab tests.
- Minimum inhibitory concentrations (MIC) varied: pexiganan 5‑10 µg/mL, h‑Lf1‑11 10‑80 µg/mL, LL‑37 20‑80 µg/mL, cecropin B 40‑160 µg/mL.
- The results point to a possible new way to control this veterinary mastitis pathogen.
Practical Outcomes
- For the biohacker community, there’s no immediate actionable protocol because the work focuses on a cow disease and uses concentrations far beyond typical human supplement doses. It may be of interest only as a very early‑stage indication that LL‑37 has antimicrobial properties beyond human immunity, but further research would be needed before any human‑focused application.
Summary
Researchers tested several antimicrobial peptides, including LL‑37, against a cow‑related infection called Prototheca bovis. Some peptides stopped the microbe from growing at low concentrations, suggesting they could be used to treat this animal disease, but the study doesn’t give any guidance for human health or everyday biohacking.
Abstract
This study evaluated the in vitro activity of antimicrobial peptides pexiganan (MSI-78), h-Lf1-11, LL-37, cecropin B, magainin-2, and fengycin B against the veterinary mastitis agent Prototheca bovis. The results showed that pexiganan, h-Lf1-11, LL-37, and cecropin B were able to inhibit the growth and had effect on algicide P. bovis isolates (n = 32). The minimum inhibitory concentration ranged from 5 to 10 µg/mL for pexiganan, and algicide effect was detected from 5 to 20 µg/mL. The minimum inhibitory concentration ranged from 10 to 80 µg/mL for h-Lf1-11, 20 to 80 µg/mL for LL-37, and 40 to 160 µg/mL for cecropin B. These findings present a promising and novel alternative for P. bovis treatment and growth control.
Study Information
pubmed
2021
2021-01-15T00:00:00.000Z
10.3168/jds.2020-18171
6
30